TPMT and HLA-DQ Allelic Variants in Relation to Drug Response, Safety and Need for Therapy Optimization in Pediatric Inflammatory Bowel Disease
Bibliographic Data
| ID | 15717508 |
|---|---|
| Authors | M Stojsić (0000-0002-0890-9732, University of Novi Sad), Ognjen Ležakov (0009-0007-0354-0458, University of Novi Sad, corresponding author), Sanja Ćeranić (Institute of Public Health of Vojvodina), Nikola Stojšić (University of Novi Sad), Marija Grdić Rajković (0009-0008-7054-3656, Institute of Public Health of Vojvodina), Srdjan Marković (0000-0001-5009-5704, University of Novi Sad), Maja Kovačević (0000-0002-8936-6820, Institute of Public Health of Vojvodina), Nina Brkić (Institute of Public Health of Vojvodina) |
| Year | 2025 |
| Volume | 12 |
| Issue | 10 |
| Pages | 1334-1334 |
| Publication date | 2025-10-04 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Children (JOURNAL) |
| Journal identifiers | ISSN: 2227-9067 • E-ISSN: 2227-9067 |
| Publisher | Multidisciplinary Digital Publishing Institute (PUBLISHER • CH) |
| DOI | 10.3390/children12101334 |
| PMID | 41153516 |
| OpenAlex | W4414865277 |
| Language | EN |
Prior to the initiation of azathioprine therapy, TPMT genotyping should be performed to prevent adverse effects and ensure optimal drug dosing. Identification of the HLA-DQA105 and HLA-DQA101 alleles plays an important role in the planning of biological therapy regimens, including decisions on dose escalation or interval shortening
Adverse effect · Allele · Azathioprine · Disease · Drug · Genotyping · Pharmacogenetics · Thiopurine methyltransferase · Immunodeficiency and Autoimmune Disorders · Inflammatory Bowel Disease · Pharmaceutical studies and practices
| Highly cited | No |
|---|